HEALTHCARE RESOURCE UTILIZATION IN LONG-TERM CARE RESIDENTS WITH AGITATION ASSOCIATED WITH DEMENTIA DUE TO ALZHEIMER’S DISEASE TREATED WITH BREXPIPRAZOLE
Author(s)
Xue Han, PhD1, Kate Mathers, PhD2, Emily S. Reese, MPH, PhD3, Debra Eisenberg, PhD4, Chad Worz, PharmD5, Amita Patel, MD6, Sanjeda Chumki, PharmD1, David Wang, PhD7, Hong Xiao, PhD8, Aaron P. Norfolk, BSc9, Ralph Valeriote, PhD9, Brittin Wagner, PhD10;
1Otsuka Pharmaceutical Development & Commercialization, Inc, Princeton, NJ, USA, 2Point Click Care, Toronto, ON, Canada, 3Otsuka Pharmaceutical Development & Commercialization, Inc, Director, Value Evidence Strategy, Princeton, NJ, USA, 4Lundbeck, Conestoga, PA, USA, 5ASCP, Alexandria, VA, USA, 6Dayton Psychiatric Associates, Dayton, OH, USA, 7Lundbeck, Deerfield, IL, USA, 8Otsuka Pharmaceutical Development & Commercialization, Tallahassee, FL, USA, 9PointClickCare, Mississauga, ON, Canada, 10PointClickCare, Bloomington, MN, USA
1Otsuka Pharmaceutical Development & Commercialization, Inc, Princeton, NJ, USA, 2Point Click Care, Toronto, ON, Canada, 3Otsuka Pharmaceutical Development & Commercialization, Inc, Director, Value Evidence Strategy, Princeton, NJ, USA, 4Lundbeck, Conestoga, PA, USA, 5ASCP, Alexandria, VA, USA, 6Dayton Psychiatric Associates, Dayton, OH, USA, 7Lundbeck, Deerfield, IL, USA, 8Otsuka Pharmaceutical Development & Commercialization, Tallahassee, FL, USA, 9PointClickCare, Mississauga, ON, Canada, 10PointClickCare, Bloomington, MN, USA
OBJECTIVES: Brexpiprazole was approved in May 2023 for agitation associated with dementia due to Alzheimer’s disease, but real-world evidence is limited, especially in the long-term care (LTC) setting. The objective for this study was to evaluate the effect of brexpiprazole on LTC HCRU outcomes for the treatment of individuals with agitation associated with dementia due to Alzheimer’s disease using electronic health records (EHR).
METHODS: This retrospective cohort study used anonymized data from the PointClickCare LTC EHR system. Adults diagnosed with Alzheimer’s disease or dementia and agitation from 2017-2025 and resided in the in LTC were included. The index date was the first filled prescription for brexpiprazole, from May 2023. HCRU outcomes were assessed 30 days before and up to 180 days after the index date. Sensitivity analyses evaluated HCRU changes when the pre-index period was extended to 90 days.
RESULTS: Of the 2461 individuals included, mean age was 81.27 years, and 62% were female. Most HCRU events decreased in frequency after initiating brexpiprazole from 30-day baseline period to the 180-day follow-up period: mean agitation episodes (16.78 vs 9.86, P<0.001); mean all incident reports (0.87 vs 0.78, P=0.005); mean emergency department visits (0.052 vs 0.036, P=0.007); and mean total physical therapy time (15.77 minutes vs 12.74 minutes, P=0.02) significantly decreased after the initiation of brexpiprazole while reports of falls stabilized (0.58 vs. 0.57, P=0.72). However, mean all-cause hospital admissions (0.078 vs 0.13 events; P=0.002) and mean all-cause hospital re-admissions (0.015 vs 0.030 events; P=0.01) significantly increased but began to decline and stabilize when examining month-to-month trends.
CONCLUSIONS: These results suggest that brexpiprazole treatment may help improve LTC HCRU event rates and ease LTC professional caregiver burden by reducing agitation symptoms and associated reporting burden faced by professional caregivers of individuals with agitation associated with dementia due to Alzheimer’s disease.
METHODS: This retrospective cohort study used anonymized data from the PointClickCare LTC EHR system. Adults diagnosed with Alzheimer’s disease or dementia and agitation from 2017-2025 and resided in the in LTC were included. The index date was the first filled prescription for brexpiprazole, from May 2023. HCRU outcomes were assessed 30 days before and up to 180 days after the index date. Sensitivity analyses evaluated HCRU changes when the pre-index period was extended to 90 days.
RESULTS: Of the 2461 individuals included, mean age was 81.27 years, and 62% were female. Most HCRU events decreased in frequency after initiating brexpiprazole from 30-day baseline period to the 180-day follow-up period: mean agitation episodes (16.78 vs 9.86, P<0.001); mean all incident reports (0.87 vs 0.78, P=0.005); mean emergency department visits (0.052 vs 0.036, P=0.007); and mean total physical therapy time (15.77 minutes vs 12.74 minutes, P=0.02) significantly decreased after the initiation of brexpiprazole while reports of falls stabilized (0.58 vs. 0.57, P=0.72). However, mean all-cause hospital admissions (0.078 vs 0.13 events; P=0.002) and mean all-cause hospital re-admissions (0.015 vs 0.030 events; P=0.01) significantly increased but began to decline and stabilize when examining month-to-month trends.
CONCLUSIONS: These results suggest that brexpiprazole treatment may help improve LTC HCRU event rates and ease LTC professional caregiver burden by reducing agitation symptoms and associated reporting burden faced by professional caregivers of individuals with agitation associated with dementia due to Alzheimer’s disease.
Conference/Value in Health Info
2026-05, ISPOR 2026, Philadelphia, PA, USA
Value in Health, Volume 29, Issue S6
Code
EE31
Topic
Economic Evaluation
Topic Subcategory
Cost/Cost of Illness/Resource Use Studies
Disease
SDC: Geriatrics, SDC: Neurological Disorders